title: Oral delivery of small RNA and DNA.
abstract: The promise of short RNA or DNA segments such as siRNAs, antisense oligonucleotides, and transcription factor decoys to treat disease has prompted nearly 40 clinical trials for RNA interference (RNAi)-based therapeutics and more than 100 clinical trials for antisense oligonucleotide-based technologies; in fact, there are promising in vivo and preclinical studies for many hundreds of technologies. Current treatment strategies are largely injection-based, so effective oral delivery platforms for oligonucleotides may result in improved patient comfort and compliance. We analyze recently developed oral delivery methods for short RNA and DNA segments.
authors: Department of Chemical Engineering, The University of Texas at Austin, Austin, TX 78712, USA. DianeCForbes@utexas.edu
authors: Diane C
authors: DC
authors: Forbes
authors: Nicholas A
authors: NA
authors: Peppas
mesh_terms: D000284:Administration, Oral; D000818:Animals; D004247:DNA / Q000008:administration & dosage*; D006801:Humans; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage*; D012313:RNA / Q000008:administration & dosage*
chemical_list: D016376:Oligonucleotides, Antisense; D012313:RNA; D004247:DNA